2006
Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study
Tierney E, Aman M, Stout D, Pappas K, Arnold LE, Vitiello B, Scahill L, McDougle C, McCracken J, Wheeler C, Martin A, Posey D, Shah B. Parent satisfaction in a multi-site acute trial of risperidone in children with autism: a social validity study. Psychopharmacology 2006, 191: 149-157. PMID: 17123125, DOI: 10.1007/s00213-006-0604-z.Peer-Reviewed Original ResearchConceptsClinical trialsClinical trial proceduresParent satisfactionDouble-blind clinical trialRandomized clinical trialsTrial proceduresResearch participationClinical responseAcute trialTreatment outcomesActive drugSimilar childrenStudy proceduresTrialsPharmacological researchAutistic disorderLearning TestPlaceboChildren's research participationEthnic minority subjectsChildrenRisperidoneWhite participantsGood allianceDrugs
2003
DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study
Zalsman G, Frisch A, Lev-Ran S, Martin A, Michaelovsky E, Bensason D, Gothelf D, Nahshoni E, Tyano S, Weizman A. DRD4 exon III polymorphism and response to risperidone in Israeli adolescents with schizophrenia: a pilot pharmacogenetic study. European Neuropsychopharmacology 2003, 13: 183-185. PMID: 12729944, DOI: 10.1016/s0924-977x(03)00006-3.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScalePossible associationAdolescent schizophrenia patientsFirst-episode schizophreniaPsychiatric Rating ScaleHigh response rateClinical responseRepeat alleleSchizophrenia patientsResponse rateSignificant associationPharmacogenetic studiesRisperidoneAdolescent inpatientsRating ScaleSchizophreniaAssociationDRD4 genotypeDRD4 geneResponseIsraeli adolescentsLarge groupPolymorphismDRD4 exon III polymorphismPatientsLow-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study
Martin A, Koenig K, Anderson GM, Scahill L. Low-Dose Fluvoxamine Treatment of Children and Adolescents with Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of Autism And Developmental Disorders 2003, 33: 77-85. PMID: 12708582, DOI: 10.1023/a:1022234605695.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderSelective serotonin reuptake inhibitor responseOpen-label studyOpen-label trialLow-dose fluvoxamineDevelopmental disordersPremature discontinuationClinical responseFluvoxamine treatmentPartial respondersMean ageSerotonin levelsSelect childrenPubertal statusInhibitor responseBehavioral activationFluvoxamineChildrenFurther investigationDisordersTreatmentGender differencesAdolescentsSubjectsTolerability